Terns Pharmaceuticals (TERN) Stock Price, News & Analysis

Company Overview

Terns Pharmaceuticals, Inc. is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation. These include inhibitors of key pathways implicated in nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), as well as programs directed at hepatocellular carcinoma. Each candidate is being investigated for its ability to modulate disease drivers such as bile acid metabolism, immune cell activation and cell‐signaling cascades involved in fibrosis. Terns leverages state‐of‐the‐art medicinal chemistry and translational biology platforms to optimize both efficacy and safety profiles across its portfolio.

Headquartered in San Diego, California, Terns Pharmaceuticals operates in a hub known for innovation in hepatology and liver disease research. The company’s management and scientific leadership bring extensive experience from established biotech and pharmaceutical organizations, with deep expertise in clinical development, regulatory strategy and commercialization planning. By combining this leadership team’s industry knowledge with strategic partnerships and academic collaborations, Terns is positioned to advance its therapeutic candidates toward regulatory milestones and, ultimately, broaden treatment options for patients suffering from severe liver diseases.

Key Stats

• Today's Range: $52.94 to $52.98
• 50-Day Range: $40.92 to $53.17
• 52-Week Range: $2.65 to $53.19
• Volume: 6.35 million shs
• Average Volume: 4.84 million shs
• Market Capitalization: $6.12 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $55.14
• Consensus Rating: Hold

Terns Pharmaceuticals Stock Analysis - MarketRank™

Terns Pharmaceuticals scored higher than 23% of companies evaluated by MarketBeat, and ranked 759th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Hold

Consensus Rating

Terns Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on 1 strong buy rating, 3 buy ratings, 10 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Terns Pharmaceuticals is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Terns Pharmaceuticals has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Terns Pharmaceuticals are expected to decrease in the coming year, from ($1.22) to ($1.67) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Terns Pharmaceuticals is -51.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Terns Pharmaceuticals is -51.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Terns Pharmaceuticals has a P/B Ratio of 5.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for TERN.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Terns Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Terns Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.25

News Sentiment

Terns Pharmaceuticals has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Terns Pharmaceuticals this week, compared to 4 articles on an average week.

Search Interest

Only 1 people have searched for TERN on MarketBeat in the last 30 days. This is a decrease of -96% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Terns Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,302,370.00 in company stock.

Percentage Held by Insiders

1.50% of the stock of Terns Pharmaceuticals is held by insiders.

Percentage Held by Institutions

98.26% of the stock of Terns Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TERN Stock Analysis - Frequently Asked Questions

How have TERN shares performed this year?

Terns Pharmaceuticals' stock was trading at $40.40 at the beginning of 2026. Since then, TERN shares have increased by 31.1% and is now trading at $52.95.

How were Terns Pharmaceuticals' earnings last quarter?

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) released its earnings results on Monday, March, 30th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.06.

When did Terns Pharmaceuticals IPO?

Terns Pharmaceuticals (TERN) raised $120 million in an initial public offering on Friday, February 5th 2021. The company issued 7,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO.

Who are Terns Pharmaceuticals' major shareholders?

Terns Pharmaceuticals' top institutional investors include Pictet Asset Management Holding SA (1.43%), Candriam S.C.A. (0.55%), Jennison Associates LLC (0.43%) and Bank of New York Mellon Corp (0.24%). Insiders that own company stock include Hongbo Lu, Amy L Burroughs, Vivo Opportunity, Llc, Emil Kuriakose, Mark J Vignola, Andrew Gengos, Melita Sun Jung and Jill M Quigley.
View institutional ownership trends.

How do I buy shares of Terns Pharmaceuticals?

Shares of TERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Terns Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Terns Pharmaceuticals investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Chevron (CVX).

Company Calendar

• Last Earnings: 3/30/2026
• Today: 5/07/2026
• Next Earnings (Estimated): 5/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TERN
• CIK: 1831363
• Web: www.ternspharma.com
• Phone: 650-525-5535
• Fax: N/A
• Employees: 40
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Terns Pharmaceuticals: $55.14
• High Price Target: $70.00
• Low Price Target: $44.50
• Potential Upside/Downside: +4.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.27
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$96.21 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -20.02%
• Return on Assets: -19.37%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 62.41
• Quick Ratio: 62.41

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.70 per share
• Price / Book: 5.46

Miscellaneous

• Outstanding Shares: 115,520,000
• Free Float: 113,788,000
• Market Cap: $6.12 billion
• Optionable: Not Optionable
• Beta: -0.37